Predicting Patient Response Before Trials Start: Pilgrim Jackson, Yatiri Bio

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/b7/c0/31/b7c031b7-44b4-c652-ffc5-1af6a1969e50/mza_3591023405865880209.jpg/600x600bb.jpg

Innovating Tomorrow's Medicine

Jeff Trickett

15 episodes

1 week ago

Dr. Jeff Trickett is a neuroscientist, biotech strategist, and author. He hosts Innovating Tomorrow’s Medicine, a podcast highlighting the people and ideas reshaping the future of healthcare. He created the show to go beyond the headlines with honest conversations from biotech founders, researchers, clinicians and investors who are turning bold ideas into real-world impact. His goal is to discover the strategies they use, the insights behind their success and breakthroughs that will define the future of medicine; while challenging the way we think about health, science, and progress.

Life Sciences

Science

RSS

All content for Innovating Tomorrow's Medicine is the property of Jeff Trickett and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/44169658/44169658-1765747219619-4bba8cf429736.jpg

Predicting Patient Response Before Trials Start: Pilgrim Jackson, Yatiri Bio

Innovating Tomorrow's Medicine

50 minutes 2 seconds

2 weeks ago

Predicting Patient Response Before Trials Start: Pilgrim Jackson, Yatiri Bio

What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start.

In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his company is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far.

What we discuss:

• How proteomic signatures differentiate responders from non-responders in AML and ovarian cancer

• Why this could reduce Phase 2 trial enrollment from 100 patients to 40—cutting costs in half

• De-risking clinical trial design and addressing patient heterogeneity

• Regulatory considerations for biomarker-driven and stratified trials

• The future of precision oncology and patient-centric trial design

This isn't incremental improvement. This is a completely different way to run trials.

About the Guest: Pilgrim Jackson is CEO of Yatiri Bio, a biotechnology company decoding proteins to predict treatment response in oncology.

About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.

🔗 Connect:

• Yatiri Bio: [https://yatiribio.com]

• Pilgrim Jackson:[https://www.linkedin.com/in/pilgrimjackson]

• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]

📧 Questions or guest suggestions? [jeffreytrickett@gmail.com]

#Biotech #ClinicalTrials #PrecisionMedicine #Proteomics #Oncology #AML #DrugDevelopment